Bay Area's ReVance Therapeutics, Inc. Prices IPO At Top Of Range, Raises $96 Million
Published: Feb 06, 2014
Wrinkle removing biotech company Revance Therapeutics raised $96 million in the Bay Area's second IPO of 2014 on Thursday. The Newark company led by CEO Dan Browne sold 6 million shares at $16 each and is expected to trade as RVNC on the Nasdaq on Thursday. Revance's market cap at its IPO price is about $284 million.
Help employers find you! Check out all the jobs and post your resume.